Abstract:Objective To investigate the effect of polyene phosphatidylcholine as supplementary therapy on immune function in patients with intrahepatic cholestasis of pregnancy (ICP). Methods A total of 100 patients were included and randomly divided into control group from which patients received standard treatment, and observation group from which patients received treatment of polyene phosphatidylcholine in addition to standard treatment.Levels of ALT, AST, TBA, IL-12, TNF-α and SOCS-3 were measured in all patients. Results No significant difference in all markers between the two groups was observed before any treatments (P > 0.05). After treatment,clinical markers of the disease post-treatment indicated patients being recovered. Levels of Ribaha, TBA, AST and ALT in the observation group were significantly decreased when compared with control group (P < 0.05). Levels of IL-12 and TNF-α were dramatically increased when compared with control group (P < 0.05). Observation group with treatment of polyene phosphatidylcholine experienced significantly higher expression of SOCS-3 while less adverse outcomes when compared with control group (P < 0.05). Conclusion Polyenoic phosphatidylcholine combined with standard treatment effectively improves the outcome of patients with ICP potentially through SOCS-3-mediated inhibition of immune function.